PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Botulinum toxin type A - Migraine (prevention)

PAD Profile : Botulinum toxin type A - Migraine (prevention) Important

Keywords :
chronic migraine, migraine prevention, migraine prophylaxis
Brand Names Include :
Botox
Important Information :
For Chronic migraine only

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Not Specified
Important Information :
Neurology teams only
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
R
NICE
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of botulinum toxin type A for the prevention of headaches in adults with chronic migraine in line with NICE TA260 (June 2012) and the locally agreed treatment pathway below.

Prescribing will be by hospital specialists only, in line with NICE TA260 using Blueteq initiation and continuation forms. Botulinum toxin type A will be considered RED on the traffic light system.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

Associated BNF Codes

04. Central Nervous System
04.07.04. Antimigraine drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More